Partner, European Patent Attorney
Simon is a member of the life sciences patent team and has considerable experience in the pharmaceutical and biotechnology sectors as well as the nanotech and Cleantech sectors. He has worked on many top selling biologics having prosecuted patent applications, run oppositions and appeals, and provided due diligence work in relation to Nutropin AQ®, Hereceptin® and Lyxumia® (lixisenatide).
His experience includes:
IAM Patent 1000 for prosecution 2014 guide says “Simon Kiddle has been a rock for Mewburn Ellis in his nearly 25-year career here. Renowned for drafting iron-clad patents, he also performs with guile on oppositions and appeals.”
Legal 500 (2014) comments: “The “thorough” and “diligent” Simon Kiddle is recommended for his expertise in the life sciences sector”. Named as a “key contact in the life sciences group” in the Legal 500 (2015). He is also considered ‘highly active on the life sciences side’ in the Legal 500 2016. Simon is once again recommended in the 2017 edition of the Legal 500 where one client describes him to be ‘efficient and reliable‘.
Managing Intellectual Property’s ‘IP Stars 2016’ says “life sciences specialist Simon Kiddle is recommended for contentious EPO work”.
Simon has extensive experience in European oppositions and appeals, original patent drafting, patent strategy for approved biologics, advising start-up companies and investors, and due diligence work. He has also been involved in multi-jurisdiction infringement/invalidity actions in the US, UK and Germany.
His clients include large and small biotechnology companies, universities and research charities.
Simon has a degree in chemistry from Oxford University.
Simon joined Mewburn Ellis LLP in 1991, qualifying as a Chartered Patent Attorney in 1994 and a European Patent Attorney in 1995. He joined the partnership in 1997.